Abstracts Archive - Page 286 of 2607 - ACR Meeting Abstracts

Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 1494 • ACR Convergence 2024
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Ioannis Parodis¹, Julius Lindblom², Alexandre Tsoi³, Dionysis Nikolopoulos⁴ and Lorenzo Beretta⁵, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: The efficacy of belimumab in treating SLE has been demonstrated in several phase 3 randomized clinical trials (RCTs). These trials showed belimumab efficacy on…
Abstract Number: 1496 • ACR Convergence 2024
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Loqmane seridi¹, Steven Leonardo², Brittney Scott³, Robert Gordon¹, cathye shu¹, Kaiyin Fei¹, Kim Lo³, Anne Stevens¹ and Sheng Gao³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
Abstract Number: 0145 • ACR Convergence 2024
Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Leila Milanfar¹, Jinoos Yazdany², Amanda Eudy³, Courtney Hoge⁴, Charmayne M. Dunlop-Thomas⁵, Patti Katz⁶ and Laura Plantinga⁷, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Duke University, Raleigh, NC, ⁴Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁶UCSF, San Rafael, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Measurement of the extent to which individuals move throughout their community and participate in social activities (“community mobility”) can provide a snapshot of how…
Abstract Number: 1425 • ACR Convergence 2024
Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
Sonia Jiménez Barrios¹, Sandra Garrote Corral², Juan Rigual³, Carlos de La Puente Bujidos³, Maria Angeles Blazquez Canamero⁴ and Jesús Loarce³, ¹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴Hospital Ramon y Cajal, Madrid, Madrid, Spain
Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…
Abstract Number: 1478 • ACR Convergence 2024
Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
Xenofon Baraliakos¹, Paul Bird², Atul Deodhar³, Dafna Gladman⁴, Philip S. Helliwell⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, Mikkel Ostergaard⁸, Enrique R. Soriano⁹, Lai-shan Tam¹⁰, Soumya Chakravarty¹¹, Evan Leibowitz¹², Cinty Gong¹³, Stephen Xu¹⁴, Thomas Fuerst¹⁵, Nadeem Saeed¹⁶, Robert Landewé¹⁷ and Philip Mease¹⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of New South Wales, Randwick, NSW, Sydney, New South Wales, Australia, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California San Diego, La Jolla, CA, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰The Chinese University of Hong Kong, New Territories, Hong Kong, ¹¹Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ¹²Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ¹³Janssen Scientific Affairs, Horsham, PA, ¹⁴Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁵Clario, San Mateo, CA, ¹⁶Clario, San Mateo, ¹⁷Amsterdam University Medical Center, Meerssen, Netherlands, ¹⁸Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with PsA can develop axial inflammation in the SI joints (SIJs) and/or spine. Although validated classification criteria for axial spondyloarthritis exist, established…
Abstract Number: 1457 • ACR Convergence 2024
Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
Gonul Hazal Koc¹, Marc R. Kok², Fazira R. Kasiem³, Jolanda Luime³, Ilja Tchetverikov⁴, Kim Wilhelm - de Jong³, Lindy A. Korswagen⁵, Jessica Bijsterbosch⁶, Yvonne P. M. Goekoop-Ruiterman⁷, Paul Baudoin⁸, Petra Kok⁹, Reinhard Bos¹⁰, radboud J.e.m. Dolhain¹¹ and Marijn Vis³, ¹Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus MC, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁵Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, ⁶Amphia Hospital, North Brabant, Netherlands, ⁷Haga Hospital, Den Haag, Netherlands, ⁸Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Reinier de Graaf Gasthuis, Delft, Netherlands, ¹⁰Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: The Strategy Treatments aiming at Minimal Disease Activity in PsA (STAMP) is a one-year randomized controlled trial designed to investigate the efficacy of two…
Abstract Number: 1470 • ACR Convergence 2024
Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement
Alen Zabotti¹, Alexis Ogdie², Masato Okada³, Rebecca Bolce⁴, Jeffrey Lisse⁵, Marcus Ngantcha⁵, mohamed taher⁵, Khai Jing Ng⁶ and Dennis McGonagle⁷, ¹Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Udine, Italy, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³St. Luke's International Hospital, Tokyo, Japan, ⁴Eli Lilly and Company, Cincinnati, OH, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Madrid, Spain, ⁷National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: Nails are a challenging body area to treat in patients (pts) with psoriatic arthritis (PsA)1. Previous research found that nail psoriasis is closely related…
Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abhishek Abhishek¹, Nicholas Peckham² and Jonathan Cook², and the VROOM Study Author Group, ¹University of Nottingham, Nottingham, United Kingdom, ²Oxford University, Oxford, United Kingdom
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…
Abstract Number: 1233 • ACR Convergence 2024
Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis
Aviya Lanis¹, Emily Steelquist², Christian Lood³ and Susan Shenoi⁴, ¹Seattle Children's Hospital, Seattle, WA, ²OHSU, Portland, OR, ³Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, ⁴Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) have impaired quality of life and increased rates of anxiety and depression (15-65%), even…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Peter C. Taylor¹, Aditi Kadakia², Jack Milligan³, Sander Strengholt², Oliver Howell³, Pankaj Patel², Sophie Barlow³ and Roberto Caporali⁴, ¹University of Oxford, Oxford, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
Abstract Number: 1482 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Atul Deodhar¹, Eva Dokoupilova², Cynthia Vizcaya³, Reema Sutariya⁴, Weibin Bao⁴, Karen Kapur³, Susanne Rohrer³ and Alan Kivitz⁵, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Altoona Center for Clinical Research, Duncansville, PA

Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
Abstract Number: 1487 • ACR Convergence 2024
Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
Fan Lian and Qingying Fang, First Affiliated Hospital of Sun Yat-sen University, guangzhou, China (People's Republic)
Background/Purpose: To compare the pregnancy outcomes of patients with systemic lupus erythematosus (SLE) complicated with thrombocytopenia and those without, and to analyze the related risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].